Last reviewed · How we verify
Enstilar
At a glance
| Generic name | Enstilar |
|---|---|
| Also known as | calcipotriene and betamethasone dipropionate, calcipotriol/betamethasone dipropionate cutaneous foam, Cutaneous foam, calcipotriene and betamethasone |
| Sponsor | L.H. Kircik, M.D. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream
- Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (PHASE3)
- A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis (PHASE4)
- Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis (PHASE4)
- Combination of Sotyktu and Enstilar for Plaque Psoriasis (PHASE4)
- A Phase III Study in Subjects With Mild to Moderate Psoriasis. (PHASE3)
- Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enstilar CI brief — competitive landscape report
- Enstilar updates RSS · CI watch RSS
- L.H. Kircik, M.D. portfolio CI